Trái phiếu GSKC
Sau đây là danh sách trái phiếu doanh nghiệp GSK PLC CEDEAR EACH REPR 1/4 ADR. Các nhà đầu tư thường lựa chọn trái phiếu của công ty vì tính ổn định cao hơn trong thời điểm thị trường biến động. Nghiên cứu giá cả, lợi suất và các số liệu thống kê khác và tìm khoản đầu tư đáng tin cậy.
Mã | Lợi suất đáo hạn % | Khối lượng | Giá % | Phiếu giảm giá % | Ngày đáo hạn | Giá trị dư nợ | Giá trị khuôn mặt | Giá trị mệnh giá tối thiểu | Bên phát hành |
|---|---|---|---|---|---|---|---|---|---|
| 117RIGLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45 | 5.57% | 8.46 K | 82.51% | 4.25% | 2045-12-18 | 370.786 M GBP | 1,000.00 GBP | 100,000.00 GBP | GlaxoSmithKline Capital Plc |
| 883GIGLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042 | 5.38% | 0 | 98.48% | 5.25% | 2042-04-10 | 477.816 M GBP | 1,000.00 GBP | 50,000.00 GBP | GlaxoSmithKline Capital Plc |
| 771ZCGLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39 | 5.34% | 0 | 110.75% | 6.38% | 2039-03-09 | 631.3 M GBP | 1,000.00 GBP | 50,000.00 GBP | GlaxoSmithKline Capital Plc |
| GGSK.GJGlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038 | 5.33% | 118 K | 110.41% | 6.38% | 2038-05-15 | 2.75 B USD | 1,000.00 USD | 2,000.00 USD | GlaxoSmithKline Capital, Inc. |
| GGSK3981911GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043 | 5.27% | 574 K | 86.78% | 4.20% | 2043-03-18 | 500 M USD | 1,000.00 USD | 2,000.00 USD | GlaxoSmithKline Capital, Inc. |
| XXS217060907GLAXOSM.CAP. MTN 20/35MTN | 5.00% | 0 | 71.92% | 1.63% | 2035-05-12 | 750 M GBP | 1,000.00 GBP | 100,000.00 GBP | GlaxoSmithKline Capital Plc |
| AAG99GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033 | 4.82% | 0 | 103.23% | 5.25% | 2033-12-19 | 574.166 M GBP | 1,000.00 GBP | 1,000.00 GBP | GlaxoSmithKline Capital Plc |
| 772WIGLAXOSMITHKLINE CAPITAL INC 5.375% GTD SNR NTS 15/04/2034 | 4.69% | 8 K | 105.28% | 5.38% | 2034-04-15 | 500 M USD | 1,000.00 USD | 1,000.00 USD | GlaxoSmithKline Capital, Inc. |
| UUS377373AH8GLAXOSM.CAP. 19/29 | 4.64% | 0 | 94.80% | 3.38% | 2029-06-01 | 1 B USD | 1,000.00 USD | 2,000.00 USD | GlaxoSmithKline Capital Plc |
| UUS377372AN7GLAXOSMITHKLINE CAP.18/28 | 4.58% | 0 | 97.71% | 3.88% | 2028-05-15 | 1.75 B USD | 1,000.00 USD | 2,000.00 USD | GlaxoSmithKline Capital, Inc. |
| XXS217060184GLAXOSM.CAP. MTN 20/28MTN | 4.50% | 0 | 88.31% | 1.25% | 2028-10-12 | 750 M GBP | 1,000.00 GBP | 100,000.00 GBP | GlaxoSmithKline Capital Plc |
| GGSK4632357GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025 | 4.12% | 12 K | 99.52% | 3.63% | 2025-05-15 | 1 B USD | 1,000.00 USD | 2,000.00 USD | GlaxoSmithKline Capital, Inc. |
| GGX5CGLAXOSM.CAP. MTN 05/25 | 3.34% | 0 | 100.65% | 4.00% | 2025-06-16 | 750 M EUR | 1,000.00 EUR | 1,000.00 EUR | GlaxoSmithKline Capital Plc |
| XXS255381776GSK CAP B.V. 22/32 MTN | 3.12% | 0 | 100.06% | 3.13% | 2032-11-28 | 700 M EUR | 1,000.00 EUR | 100,000.00 EUR | GSK Capital BV |
| XXS182282979GLAXOSM.CAP. MTN 18/30MTN | 2.87% | 0 | 94.27% | 1.75% | 2030-05-21 | 750 M EUR | 1,000.00 EUR | 100,000.00 EUR | GlaxoSmithKline Capital Plc |
| XXS168152035GLAXOSM.CAP. MTN 17/29 | 2.71% | 0 | 93.96% | 1.38% | 2029-09-12 | 500 M EUR | 1,000.00 EUR | 100,000.00 EUR | GlaxoSmithKline Capital Plc |
| XXS255381768GSK CAP B.V. 22/27 MTN | 2.70% | 0 | 100.88% | 3.00% | 2027-11-28 | 500 M EUR | 1,000.00 EUR | 100,000.00 EUR | GSK Capital BV |
| GGX5BGLAXOSM.CAP. MTN 17/26 | 2.56% | 0 | 97.21% | 1.00% | 2026-09-12 | 700 M EUR | 1,000.00 EUR | 100,000.00 EUR | GlaxoSmithKline Capital Plc |
| XXS182282812GLAXOSM.CAP. MTN 18/26MTN | 2.54% | 0 | 98.09% | 1.25% | 2026-05-21 | 1 B EUR | 1,000.00 EUR | 100,000.00 EUR | GlaxoSmithKline Capital Plc |
| XXS114760579GLAXOSM.CAP. MTN 14/24 | 1.45% | 0 | 99.93% | 1.38% | 2024-12-02 | 1 B EUR | 1,000.00 EUR | 100,000.00 EUR | GlaxoSmithKline Capital Plc |
| 117RNGLAXOSMITHKLINE CAPITAL PLC 3.375% GTD SNR EMTN 20/12/2027 | −0.52% | 0 | 112.19% | 3.38% | 2027-12-20 | 307.77 M GBP | 1,000.00 GBP | 100,000.00 GBP | GlaxoSmithKline Capital Plc |
| AAQ72GLAXOSMITHKLINE CAPITAL PLC 0.883% GTD SNR EMTN 21/09/20 | — | — | — | 0.88% | 2028-09-21 | 42.5 B JPY | 100,000,000.00 JPY | — | GlaxoSmithKline Capital Plc |